Takeda Secures Option for Global License of Olverembatinib from Ascentage Pharma

 June 18, 2024 Osaka, Japan & Cambridge, Mass., United States Takeda today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor…